Trump to impose 100% tariff on China starting November 1
Investing.com - RBC Capital raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN), a prominent biotechnology company with a market capitalization of $60.58 billion, to $704.00 from $695.00 on Wednesday, while maintaining a Sector Perform rating on the stock. According to InvestingPro analysis, the company maintains excellent financial health with a "GREAT" overall score.
The price target increase reflects RBC’s expectation that Regeneron’s Dupixent drug is positioned for a "meaningful beat" based on continued steady growth shown in third-party prescription and sales data. RBC has increased its estimate for Dupixent to $4.73 billion, compared to the consensus estimate of $4.59 billion. This growth aligns with the company’s overall revenue growth of 5.38% over the last twelve months.
The growth in Dupixent sales likely reflects expansion across multiple indications including COPD (chronic obstructive pulmonary disease), according to RBC’s analysis. The firm believes Street estimates for Eylea and high-dose (HD) formulations appear "reasonably achievable."
RBC noted some uncertainty around a potential top and bottom line beat due to known Libtayo inventory dynamics and less predictability for ex-U.S. Eylea collaboration revenues.
While RBC sees room for upside in Regeneron’s fundamental valuation, the firm expressed uncertainty whether high-dose label enhancements, LAG-3 data, or the approach of the Sanofi development payoff will significantly move the stock without greater clarity on Dupixent lifecycle or business development bringing in a meaningful medium-term sales driver. Trading at a P/E ratio of 14.63, InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other top US stocks.
In other recent news, Regeneron Pharmaceuticals, Inc. announced an expected acquired in-process research and development (IPR&D) charge of approximately $83 million in its third-quarter 2025 financial results. This charge is primarily linked to an $80 million up-front payment to Hansoh Pharmaceuticals Group Company Limited as part of a license agreement. Additionally, Regeneron reached a settlement with Formycon AG, allowing Formycon to launch its Eylea biosimilar in the U.S. by the fourth quarter of 2026. The U.S. Food and Drug Administration approved Regeneron’s Evkeeza for treating children aged 1 to less than 5 years with homozygous familial hypercholesterolemia. Furthermore, Regeneron’s Phase 3 Optima trial of garetosmab showed a significant reduction in new bone lesions in adults with fibrodysplasia ossificans progressiva, achieving a reduction of 90% or more. These developments follow recent advancements in Regeneron’s research and collaborations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.